PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20158569-11 2011 Combination of statins with aspirin and/or Indo resulted in complete inhibition of the synergistic IL-6 production. Indomethacin 43-47 interleukin 6 Homo sapiens 99-103 20158569-8 2011 The standard anti-inflammatory drugs aspirin and indomethacin (Indo) reduced the synergistic IL-6 production by 60%. Indomethacin 49-61 interleukin 6 Homo sapiens 93-97 21710624-10 2011 Indomethacin diminished the accumulation of microglia/macrophages and IL-6 production after H/I. Indomethacin 0-12 interleukin 6 Homo sapiens 70-74 16111494-5 2005 Indomethacin, a common nonsteroidal anti-inflammatory drug (NSAID), had no effect on microglial chemotaxis or phagocytosis, but did significantly inhibit the enhanced production of IL-6 after Abeta opsonization. Indomethacin 0-12 interleukin 6 Homo sapiens 181-185 19201813-6 2009 In accordance with ozone-induced increases in PGE(2) levels, cyclooxygenase inhibition with indomethacin partially abolished IL-6 secretion. Indomethacin 92-104 interleukin 6 Homo sapiens 125-129 17331441-6 2007 Indomethacin significantly inhibited IL-6 and IL-11 production in LPS-stimulated HGF. Indomethacin 0-12 interleukin 6 Homo sapiens 37-41 20158569-8 2011 The standard anti-inflammatory drugs aspirin and indomethacin (Indo) reduced the synergistic IL-6 production by 60%. Indomethacin 63-67 interleukin 6 Homo sapiens 93-97 20946124-9 2011 BK-induced release of IL-6, but not of IL-8, was partially inhibited by indomethacin (10 microM) and nordihydroguaiaretic acid (10 microM). Indomethacin 72-84 interleukin 6 Homo sapiens 22-26 14991990-0 2003 [Effect of indomethacin on expression of interleukin-6 caused by lipopolysaccharide in rheumatoid arthritic patients" synoviocyte]. Indomethacin 11-23 interleukin 6 Homo sapiens 41-54 15379866-6 2004 Moreover, indomethacin was demonstrated to increase the expression of interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) in a dose-dependent fashion. Indomethacin 10-22 interleukin 6 Homo sapiens 70-83 15379866-6 2004 Moreover, indomethacin was demonstrated to increase the expression of interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) in a dose-dependent fashion. Indomethacin 10-22 interleukin 6 Homo sapiens 85-89 14706622-6 2004 Western immunoblotting and indirect cellular immunofluorescence showed that indomethacin and ibuprofen induce Hsc70 nuclear translocation at concentrations previously shown to induce HSF DNA-binding activity. Indomethacin 76-88 interleukin 6 Homo sapiens 183-186 14991990-1 2003 AIM: To study the effects of indomethacin on interleukin-6 (IL-6) expression stimulated with lipopolysaccharide (LPS) in rheumatoid arthritic patients" synoviocyte. Indomethacin 29-41 interleukin 6 Homo sapiens 45-58 14991990-1 2003 AIM: To study the effects of indomethacin on interleukin-6 (IL-6) expression stimulated with lipopolysaccharide (LPS) in rheumatoid arthritic patients" synoviocyte. Indomethacin 29-41 interleukin 6 Homo sapiens 60-64 14991990-7 2003 Indomethacin at concentrations of 1 x 10(-7)-1 x 10(-5) mol.L-1 obviously inhibited the protein secretion and mRNA expression of IL-6 in FLS cultured with the supernatant from U937 cell stimulated with LPS, and the inhibitory effects increased as the concentrations of indomethacin increased. Indomethacin 0-12 interleukin 6 Homo sapiens 129-133 14991990-7 2003 Indomethacin at concentrations of 1 x 10(-7)-1 x 10(-5) mol.L-1 obviously inhibited the protein secretion and mRNA expression of IL-6 in FLS cultured with the supernatant from U937 cell stimulated with LPS, and the inhibitory effects increased as the concentrations of indomethacin increased. Indomethacin 269-281 interleukin 6 Homo sapiens 129-133 14991990-8 2003 CONCLUSION: Indomethacin can inhibit the increase of IL-6 expression caused by supernatant of U937 cells stimulated with LPS in FLS. Indomethacin 12-24 interleukin 6 Homo sapiens 53-57 12594059-5 2003 Actinomycin D (a transcription inhibitor), dexamethasone, indomethacin, IL-4, and IL-13 (Th(2) type cytokines) inhibited the expression of IL-6 by BK. Indomethacin 58-70 interleukin 6 Homo sapiens 139-143 12891120-7 2003 RESULTS: PGE(2) or 11-deoxy-PGE(1) (EP 2/3/4 agonist) reversed partially the indomethacin suppression of IL-6 secretion from explant cultures, whereas butaprost (EP2 receptor agonist) and sulprostone (EP 1/3 receptor agonist) had no effect. Indomethacin 77-89 interleukin 6 Homo sapiens 105-109 12242082-4 2002 This study investigated the effect of five days of oral indomethacin treatment (75 mg per day) on the serum concentrations of IL-6, IL-10, IL-12, and TNF-alpha induced by exercising healthy volunteers. Indomethacin 56-68 interleukin 6 Homo sapiens 126-130 12242082-7 2002 During and after strenuous physical exercise, indomethacin treatment blunted serum IL-6, and augmented TNF-alpha and IL-10. Indomethacin 46-58 interleukin 6 Homo sapiens 83-87 12017180-5 2002 However, indomethacin enhanced the cytokine-stimulated IL-6 mRNA synthesis by approximately 1.7 to approximately 3.4-fold. Indomethacin 9-21 interleukin 6 Homo sapiens 55-59 12056853-10 2002 Reducing PGE(2) synthesis by Indomethacin [a cyclo-oxygenase (COX) -1 and -2 inhibitor] reduced IL-6 levels in all osteoarthritic Ob, whereas Naproxen (a more selective COX-2 inhbitor) reduced PGE(2) and IL-6 levels only in the high osteoarthritic group. Indomethacin 29-41 interleukin 6 Homo sapiens 96-100 11298095-5 2001 Cultured tumour cells showed IL-6 protein synthesis, and nonsteroidal anti-inflammatory drugs such as naproxen and indomethacin directly inhibited IL-6 release. Indomethacin 115-127 interleukin 6 Homo sapiens 147-151 11950021-10 2002 ACECLO, DICLO, INDO, NIM significantly inhibited basal and IL-1beta stimulated IL-6 production; CELE and IBUP only inhibited IL-1beta stimulated IL-6 production; and ROFE and PIROX had no significant effects. Indomethacin 15-19 interleukin 6 Homo sapiens 79-83 11842936-3 2002 Indomethacin, a cyclooxygenase inhibitor, significantly enhanced IL-1beta-induced IL-6 production by HGF, although it completely inhibited IL-1beta-induced PGE2 production. Indomethacin 0-12 interleukin 6 Homo sapiens 82-86 11007619-13 2000 The pharmacologic agents (ciprofloxacin, pentoxifylline, and indomethacin) that can modulate the release of bone resorbing mediators such as PGE(2), TNF-alpha, IL-1, and IL-6 release from human monocytes. Indomethacin 61-73 interleukin 6 Homo sapiens 170-174 11121687-6 2000 In addition, indomethacin reduced the production of thrombin-induced IL-6 and IL-10 (p<0.05) at physiological concentrations. Indomethacin 13-25 interleukin 6 Homo sapiens 69-73 11007619-7 2000 In contrast to ciprofloxacin, indomethacin was not a potent inhibitor of TNF-alpha production but potentiated IL-6 production in titanium-stimulated monocytes. Indomethacin 30-42 interleukin 6 Homo sapiens 110-114 11121687-7 2000 Indomethacin reduced the production of LPS-induced IL-6, IL-1 beta and IL-10 (p<0.05) at the highest indomethacin concentration tested. Indomethacin 0-12 interleukin 6 Homo sapiens 51-55 11121687-9 2000 It is concluded that indomethacin may reduce the thrombin-induced inflammatory reaction by decreasing IL-6 through inhibition of PGE2 synthesis. Indomethacin 21-33 interleukin 6 Homo sapiens 102-106 11121687-10 2000 This IL-6 reduction may be relevant for the ability of indomethacin to reduce the risk of Alzheimer"s disease. Indomethacin 55-67 interleukin 6 Homo sapiens 5-9 10467171-6 1999 Actinomycin D, cycloheximide, indomethacin, and NS-398 (COX-2 inhibitor) suppressed the production of IL-6 and PGE(2). Indomethacin 30-42 interleukin 6 Homo sapiens 102-106 10772282-1 2000 The in vitro effect of indomethacin (IM) on the production of interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)alpha by cord blood mononuclear cells (CBMC) from preterm newborns was compared to that of peripheral blood MC of adults (PBMC). Indomethacin 37-39 interleukin 6 Homo sapiens 86-90 10657738-8 1999 Similarly, IL-6 increased the activity of CRH promoter in a dose-dependent fashion, an effect partially reversed by indomethacin. Indomethacin 116-128 interleukin 6 Homo sapiens 11-15 10652584-6 1999 SA, as well as indomethacin (INDO), reduced the synthesis of IL-6 and -11, at both the protein and mRNA levels, in the two cell lines producing these cytokines (MDA-MB-231 and Hs578T). Indomethacin 15-27 interleukin 6 Homo sapiens 61-73 10393680-8 1999 In explants, indomethacin 10 micromol/L or mefenamic acid 10 micromol/L abolished PGE2 secretion and significantly reduced IL-1beta and IL-6 secretion. Indomethacin 13-25 interleukin 6 Homo sapiens 136-140 10652584-6 1999 SA, as well as indomethacin (INDO), reduced the synthesis of IL-6 and -11, at both the protein and mRNA levels, in the two cell lines producing these cytokines (MDA-MB-231 and Hs578T). Indomethacin 29-33 interleukin 6 Homo sapiens 61-73 10652584-7 1999 This latter effect seemed to be mediated by PGE2 since SA and INDO reduced PGE2 levels in MDA-MB-231 and Hs578T cells, PGE2 was not detected in MCF-7 and T-47D cells and exogenous PGE2 increased IL-6 and -11 expression by MDA-MB-231 cells. Indomethacin 62-66 interleukin 6 Homo sapiens 195-207 9449430-6 1997 The non-specific cyclooxygenase inhibitor indomethacin and BF389 only suppressed the IL-6 release by post-mortem astrocyte culture A157. Indomethacin 42-54 interleukin 6 Homo sapiens 85-89 10388637-9 1999 Indomethacin also reduced the release of interleukin-1beta (IL-1beta) (from 166 pg/ml to 9.8 pg/ml, p =0.04, n=5) and interleukin-6 (IL-6) (from 119 ng/ml to 57 ng/ml, p=0.028, n=6), but had no effect on monocyte chemotactic protein 1 or matrix metalloproteinase-9 secretion. Indomethacin 0-12 interleukin 6 Homo sapiens 133-137 10388637-11 1999 Indomethacin reduces the production of PGE2, IL-1beta and IL-6, suggesting that cyclo-oxygenase-2 inhibitors may control the inflammation in the aneurysm wall and potentially limit AAA growth. Indomethacin 0-12 interleukin 6 Homo sapiens 58-62 10396075-2 1999 Indo may block production of cytokines such as Il-6 in accessory cells that are critical for B-cell growth, viability and maturation, or it may directly target B cells via PPAR-gamma receptors. Indomethacin 0-4 interleukin 6 Homo sapiens 47-51 10361345-5 1999 Indomethacin diminished secretion of PGE2, IL-1beta and IL-6 by AAA explants (see Table below). Indomethacin 1-13 interleukin 6 Homo sapiens 57-61 10361345-8 1999 Indomethacin reduces PGE2, IL-1beta and IL-6 synthesis in aneurysm tissue and NSAIDs appear to reduce AAA growth. Indomethacin 1-13 interleukin 6 Homo sapiens 41-45 9858064-4 1998 Both indomethacin and M-5011 augmented interleukin (IL)-2 production, whereas they suppressed IL-6 production both at the protein and mRNA levels. Indomethacin 5-17 interleukin 6 Homo sapiens 94-98 9449430-8 1997 Addition of exogenous PGE2 prevented the inhibitory effect of indomethacin and BF389 on the IL-1beta-activated IL-6 release from A157 astrocytes and largely potentiated the IL-1-induced release of IL-6 from all astrocytes/astroglioma cells tested. Indomethacin 62-74 interleukin 6 Homo sapiens 111-115 8587236-7 1995 Treatment of MC with the cycloxygenase inhibitor indomethacin resulted in partial inhibition (37%) of IL-6 production but had no effect on IL-8 generation. Indomethacin 49-61 interleukin 6 Homo sapiens 102-106 9364409-6 1997 Production of the part anti-inflammatory cytokine IL-6, was significantly increased by therapeutic concentrations of meloxicam, as well as by indomethacin. Indomethacin 142-154 interleukin 6 Homo sapiens 50-54 9112422-5 1997 Furthermore, we showed that specific inhibition of the cyclooxygenase pathway by indomethacin completely blocked the steroidogenic effect of IL-6 while the effect of IL-3 was not affected. Indomethacin 81-93 interleukin 6 Homo sapiens 141-145 9309381-4 1997 Both indomethacin (5 x 10(-8)-5 x 10(-6) M) and SK&F 86002 (5 x 10(-7)-10(-5) M) markedly inhibited the IL6 release and totally inhibited resorption at all concentrations tested. Indomethacin 5-17 interleukin 6 Homo sapiens 108-111 8813652-6 1996 Indomethacin increased mucosal injury and enhanced the TNF generation but reduced the release of IL-6 from the gastric mucosa. Indomethacin 0-12 interleukin 6 Homo sapiens 97-101 11859379-8 1996 This inhibition of IL-6 expression by NDGA and indomethacin was dose responsive and also reversible with the addition of exogenous prostaglandin E(2) (PGE(2)) or leukotriene B(4) (LTB(4)). Indomethacin 47-59 interleukin 6 Homo sapiens 19-23 9401927-4 1997 This IL-1 alpha, IL-1 beta, or TNF-alpha-induced IL-6 production was enhanced, but the cAMP accumulation they induced was inhibited by the addition of indomethacin. Indomethacin 151-163 interleukin 6 Homo sapiens 49-53 8841895-8 1996 Moreover, inclusion of indomethacin caused a 20% reduction in IL-6 production and totally eliminated PGE2 production. Indomethacin 23-35 interleukin 6 Homo sapiens 62-66 8724299-4 1996 While all cytokines were markedly stimulated by IL-1 alpha), co-addition of the cyclooxygenase inhibitor indomethacin enhanced IL-8 and GMCSF levels, but caused a reduction in IL-6 expression. Indomethacin 105-117 interleukin 6 Homo sapiens 176-180 8724299-5 1996 The addition of PGE2 to cultures stimulated with IL-1 alpha and indomethacin resulted increases in IL-6 mRNA and protein expression while causing a concomitant reduction in GMCSF protein and mRNA expression. Indomethacin 64-76 interleukin 6 Homo sapiens 99-103 8597883-1 1995 We performed an open, between patients, placebo controlled study in order to evaluate the effect of the treatment with the non steroidal anti inflammatory drugs indomethacin, diclofenac and naproxen on the concentrations of the cytokines IL-1 beta and IL-6 and of the neuropeptide substance P in plasma and synovial fluid of 24 rheumatoid arthritis patients. Indomethacin 161-173 interleukin 6 Homo sapiens 252-256 7877083-4 1994 IL-6 secretion from either IL-1 beta- or TNF-alpha-stimulated HGF was enhanced by the inhibition of PGE2 synthesis with indomethacin. Indomethacin 120-132 interleukin 6 Homo sapiens 0-4 8520508-3 1995 Indomethacin, a potent inhibitor of cyclo-oxygenase and of PGE2 synthesis, significantly inhibits IL-6 production (but not IL-1 production) by 35% to 90% depending on the different MM patients studied and concurrently to that of PGE2. Indomethacin 0-12 interleukin 6 Homo sapiens 98-102 8589268-7 1995 Indomethacin (IM) enhanced TNF production in all the eight TCC that were established from a patient with human T lymphotrophic virus type 1 uveitis or pulmonary sarcoidosis, and suppressed IL-6 production in six of the eight TCC, without affecting their low levels of PGE2 production. Indomethacin 0-12 interleukin 6 Homo sapiens 189-193 8589268-7 1995 Indomethacin (IM) enhanced TNF production in all the eight TCC that were established from a patient with human T lymphotrophic virus type 1 uveitis or pulmonary sarcoidosis, and suppressed IL-6 production in six of the eight TCC, without affecting their low levels of PGE2 production. Indomethacin 14-16 interleukin 6 Homo sapiens 189-193 1761639-7 1991 Monocyte interleukin-6 downregulation by interleukin-4 is dose dependent and occurs whether Fc gamma RI cross-linking, muramyl dipeptide, indomethacin plus muramyl dipeptide, or interferon-gamma plus muramyl dipeptide is the interleukin-6 inducing stimulus. Indomethacin 138-150 interleukin 6 Homo sapiens 9-22 8476047-8 1993 When the cyclooxygenase inhibitor indomethacin (10 microM) was added to cultures, the production of PGE2 by KC was prevented, and in arginine-depleted cultures, IL-1 and IL-6 production was upregulated (P < 0.05). Indomethacin 34-46 interleukin 6 Homo sapiens 170-174 8003632-4 1994 Levels of IL-6 resulting from OM and IL-1 alpha stimulation could be reduced by indomethacin (10(-6) M) and restored again by also adding PGE2. Indomethacin 80-92 interleukin 6 Homo sapiens 10-14 1632677-8 1992 When the cyclo-oxygenase inhibitor indomethacin (1 x 10(-5) M) was added to cultures, the PGE2 production was inhibited, and IL-6 production was upregulated (p less than 0.05) in arginine-depleted cultures. Indomethacin 35-47 interleukin 6 Homo sapiens 125-129 15888106-6 2005 RESULTS: Indomethacin significantly enhanced IL-1alpha-induced IL-6 production by PDL cells, although it completely inhibited IL-1alpha-induced PGE2 production. Indomethacin 9-21 interleukin 6 Homo sapiens 63-67 2012982-5 1991 Both Nal and Indo abolished the febrile rises evoked by IFN, TNF, and IL6. Indomethacin 13-17 interleukin 6 Homo sapiens 70-73 1814850-2 1991 Indomethacin and Y-9223, a novel cyclo-oxygenase inhibitor, inhibited the increases in the IL-6 level in the culture medium of both mitogen-stimulated adherent cells and non-adherent cells fractionated from mononuclear cells. Indomethacin 0-12 interleukin 6 Homo sapiens 91-95 1814850-3 1991 Northern blotting showed that the mitogen-induced increase in the expression of IL-6 mRNA was inhibited by indomethacin and Y-9223, indicating that these agents inhibit IL-6 biosynthesis. Indomethacin 107-119 interleukin 6 Homo sapiens 80-84 1814850-3 1991 Northern blotting showed that the mitogen-induced increase in the expression of IL-6 mRNA was inhibited by indomethacin and Y-9223, indicating that these agents inhibit IL-6 biosynthesis. Indomethacin 107-119 interleukin 6 Homo sapiens 169-173 32292576-6 2020 Injection of Mobilan induced signs of self-resolving inflammation not present in placebo-injected patients, including transient elevation of PSA and cytokine (G-CSF, IL-6) levels, and increased lymphoid infiltration in prostate tissue. Indomethacin 13-20 interleukin 6 Homo sapiens 166-170 6573232-2 1983 In initial experiments, the inhibitory action of histamine-induced suppressor factor (HSF) on lymphocyte proliferation was documented to be reduced by the addition of indomethacin (1 microgram/ml). Indomethacin 167-179 interleukin 6 Homo sapiens 49-84 6573232-2 1983 In initial experiments, the inhibitory action of histamine-induced suppressor factor (HSF) on lymphocyte proliferation was documented to be reduced by the addition of indomethacin (1 microgram/ml). Indomethacin 167-179 interleukin 6 Homo sapiens 86-89 6573232-3 1983 Moreover, the addition of exogeneous PGE2 (10(-7)-10(-8) M) to mononuclear cell cultures reconstituted HSF activity in the presence of indomethacin. Indomethacin 135-147 interleukin 6 Homo sapiens 103-106 30296325-6 2018 RESULTS: The intraoperative pupil diameter was correlated with the expression of IL-6 after the femtosecond laser procedure in the FLACS indomethacin group (r = -0.53; P = .07). Indomethacin 137-149 interleukin 6 Homo sapiens 81-85 29761497-9 2018 The indomethacin significantly attenuated the increases of PGE2 , IL-6, and IL-8 expression in cells stimulated with compressive force or mechanical vibration combined with compressive force. Indomethacin 4-16 interleukin 6 Homo sapiens 66-70 28887458-7 2017 Inhibition of 15-PGDH using either indomethacin or SW033291 significantly reduced the further conversion of 15-epi-LXA4 and MaR1 and regulated expression of IL-6, PDPN and STAT-1. Indomethacin 35-47 interleukin 6 Homo sapiens 157-161 23331485-11 2013 CONCLUSION: The COX inhibitors indomethacin and celecoxib reduce the expression of inflammatory factors, such as COX-2 and IL-6, in FLS from the TMJ via suppression of PGE2 production. Indomethacin 31-43 interleukin 6 Homo sapiens 123-127 27181326-11 2016 The effect of IL-6 on the LCR, but not elevated body temperature, was blocked by pretreatment with indomethacin. Indomethacin 99-111 interleukin 6 Homo sapiens 14-18